SCHEMBL16366709

SCHEMBL16366709

CCCCCn1c(=O)oc2cc(Cl)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 3/20 0.54
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 1/20 0.53
CYP3A4 P08684 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
PIK3CB P42338 1/20 0.53
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TP53 P04637 1/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
KMO O15229 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
THRB P10828 1/20 0.48
IDO1 P14902 2/20 0.48
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830757 0.96 TDP1 (0.54) TMEM97TDP1LMNACYP3A4HPGD
SCHEMBL3028907 0.85 PIK3CB (0.55) TMEM97TDP1LMNACYP3A4HPGD
SCHEMBL14044191 0.83 LMNA (0.59) TDP1LMNACYP3A4HPGDHSD17B10
SCHEMBL17817481 0.82 LMNA (0.47) TDP1LMNACYP3A4HPGDHSD17B10
SCHEMBL3031599 0.81 TMEM97 (0.55) TMEM97
SCHEMBL5503439 0.79 ALDH1A1 (0.81) LMNAHPGDALDH1A1NPSR1TP53
SCHEMBL10991734 0.79 IDO1 (0.54) TMEM97TDP1LMNACYP3A4HPGD
SCHEMBL25320405 0.78 ALDH1A1 (0.84) LMNAHPGDALDH1A1NPSR1TP53
SCHEMBL14288460 0.78 ALDH1A1 (0.84) LMNAHPGDALDH1A1NPSR1TP53
SCHEMBL4423635 0.77 TP53 (0.63) TDP1LMNACYP3A4HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
WO-2014204859-A2 BCL6 INHIBITORS AS ANTICANCER AGENTS MELNICK ARI (US) 2014-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A TMEM97 3198/4885TDP1 2505/4885LMNA 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.